• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

溶出度试验中相似因子评估的另一种方法。

An alternative method to the evaluation of similarity factor in dissolution testing.

作者信息

Costa P

机构信息

Serviço de Tecnologia Farmacêutica, Faculdade de Farmácia, Universidade do Porto, Rua Aníbal Cunha, 164, 4050-047, Porto, Portugal.

出版信息

Int J Pharm. 2001 Jun 4;220(1-2):77-83. doi: 10.1016/s0378-5173(01)00651-2.

DOI:10.1016/s0378-5173(01)00651-2
PMID:11376969
Abstract

This paper addresses an alternative method to the evaluation of similarity factor f(2) as a criterion for assessment of similarity between two in-vitro dissolution profiles as proposed in the SUPAC-IR Guidance (1995). Diltiazem hydrochloride Sustained-Release (SR) tablets were tested and the following independent-model dissolution parameters were used: t10% dissolution time, t25% dissolution time, t50% dissolution time, mean dissolution time (MDT), dissolution efficiency (DE) at t(120), and at t(360). To compare the dissolution profiles, several release models were tested such as Higuchi, zero order, first order, Baker-Lonsdale, Hixson-Crowell, Weibull and Korsmeyer-Peppas. The similarities between two in-vitro dissolution profiles were assessed by pair-wise independent-model procedures such as difference factor (f1), similarity factor (f2) and Rescigno index (xi1 and xi2). The in vitro release kinetics of diltiazem hydrochloride sustained release tablets were evaluated using USP apparatus 2.

摘要

本文探讨了一种替代方法,用于评估相似性因子f(2),作为如SUPAC-IR指南(1995年)中所提出的评估两种体外溶出曲线相似性的标准。对盐酸地尔硫卓缓释片进行了测试,并使用了以下独立模型溶出参数:10%溶出时间、25%溶出时间、50%溶出时间、平均溶出时间(MDT)、在t(120)和t(360)时的溶出效率(DE)。为了比较溶出曲线,测试了几种释放模型,如Higuchi模型、零级模型、一级模型、Baker-Lonsdale模型、Hixson-Crowell模型、Weibull模型和Korsmeyer-Peppas模型。通过成对独立模型程序,如差异因子(f1)、相似性因子(f2)和Rescigno指数(xi1和xi2),评估两种体外溶出曲线之间的相似性。使用美国药典装置2评估盐酸地尔硫卓缓释片的体外释放动力学。

相似文献

1
An alternative method to the evaluation of similarity factor in dissolution testing.溶出度试验中相似因子评估的另一种方法。
Int J Pharm. 2001 Jun 4;220(1-2):77-83. doi: 10.1016/s0378-5173(01)00651-2.
2
Divisability of diltiazem matrix sustained-release tablets.地尔硫䓬骨架型缓释片的可压性
Pharm Dev Technol. 2001 Aug;6(3):343-51. doi: 10.1081/pdt-100002616.
3
Influence of dissolution medium agitation on release profiles of sustained-release tablets.溶出介质搅拌对缓释片释放曲线的影响
Drug Dev Ind Pharm. 2001 Sep;27(8):811-7. doi: 10.1081/ddc-100107244.
4
Testing lyoequivalency for three commercially sustained-release tablets containing diltiazem hydrochloride.对三种市售盐酸地尔硫卓缓释片进行溶出度等效性测试。
Acta Pol Pharm. 2010 Jan-Feb;67(1):93-7.
5
Modeling and comparison of dissolution profiles.溶出曲线的建模与比较
Eur J Pharm Sci. 2001 May;13(2):123-33. doi: 10.1016/s0928-0987(01)00095-1.
6
Evaluation of in vitro dissolution profiles of modified-release metoprolol succinate tablets crushed using mortar and pestle technique.采用研钵和杵技术粉碎的缓释琥珀酸美托洛尔片的体外溶出度评价。
Eur J Pharm Sci. 2024 Mar 1;194:106694. doi: 10.1016/j.ejps.2024.106694. Epub 2024 Jan 7.
7
Quality surveillance of immediate release aceclofenac tablets (100 mg) available in local market.对当地市场上现有的速释型醋氯芬酸片(100毫克)进行质量监测。
Pak J Pharm Sci. 2017 Nov;30(6):2193-2201.
8
Drug release kinetic analysis and prediction of release data via polymer molecular weight in sustained release diltiazem matrices.通过聚合物分子量对缓释地尔硫䓬基质中的药物释放动力学进行分析及对释放数据进行预测。
Drug Res (Stuttg). 2014 Mar;64(3):118-23. doi: 10.1055/s-0033-1353186. Epub 2013 Aug 28.
9
Assessment of xanthan gum based sustained release matrix tablets containing highly water-soluble propranolol HCl.含高水溶性盐酸普萘洛尔的黄原胶基缓释骨架片的评估。
Acta Pol Pharm. 2013 Mar-Apr;70(2):283-9.
10
Formulation development and evaluation of Diltiazem HCl sustained release matrix tablets using HPMC K4M and K100M.使用羟丙甲纤维素K4M和K100M研制和评价盐酸地尔硫卓缓释骨架片
Pak J Pharm Sci. 2013 Jul;26(4):653-63.

引用本文的文献

1
Polymeric nanocomposite hydrogel scaffold for jawbone regeneration: The role of rosuvastatin calcium-loaded silica nanoparticles.用于颌骨再生的聚合物纳米复合水凝胶支架:负载瑞舒伐他汀钙的二氧化硅纳米颗粒的作用。
Int J Pharm X. 2023 Oct 2;6:100213. doi: 10.1016/j.ijpx.2023.100213. eCollection 2023 Dec 15.
2
A Critical Overview of FDA and EMA Statistical Methods to Compare In Vitro Drug Dissolution Profiles of Pharmaceutical Products.美国食品药品监督管理局(FDA)与欧洲药品管理局(EMA)用于比较药品体外溶出曲线的统计方法批判性概述
Pharmaceutics. 2021 Oct 15;13(10):1703. doi: 10.3390/pharmaceutics13101703.
3
Liqui-Mass Technology as a Novel Tool to Produce Sustained Release Liqui-Tablet Made from Liqui-Pellets.
液状物料技术作为一种制备由液状微丸制成的缓释液体制剂的新型工具。
Pharmaceutics. 2021 Jul 9;13(7):1049. doi: 10.3390/pharmaceutics13071049.
4
Design and Characterization of Spray-Dried Proliposomes for the Pulmonary Delivery of Curcumin.喷雾干燥前体脂质体制备及其用于肺部递送姜黄素的研究。
Int J Nanomedicine. 2021 Apr 7;16:2667-2687. doi: 10.2147/IJN.S306831. eCollection 2021.
5
Rapid releasing naproxen Liqui-Pellet using effervescent agent and neusilin US2.使用泡腾剂和硅铝酸盐US2的快速释放萘普生液状小丸
Iran J Basic Med Sci. 2021 Jan;24(1):108-115. doi: 10.22038/ijbms.2020.51697.11729.
6
In SituForming Microparticles for Controlled Release of Rivastigmine: In Vitro Optimization and In Vivo Evaluation.用于控释卡巴拉汀的原位形成微粒:体外优化与体内评价
Pharmaceuticals (Basel). 2021 Jan 14;14(1):66. doi: 10.3390/ph14010066.
7
Hydrogel-based matrices for controlled drug delivery of etamsylate: Prediction of plasma profiles.用于乙磺半胱氨酸控释给药的水凝胶基基质:血浆浓度曲线预测
Saudi Pharm J. 2020 Dec;28(12):1704-1718. doi: 10.1016/j.jsps.2020.10.016. Epub 2020 Nov 6.
8
Electro-Hydrodynamic Drop-on-Demand Printing of Aqueous Suspensions of Drug Nanoparticles.药物纳米颗粒水悬浮液的电流体动力按需喷射打印
Pharmaceutics. 2020 Oct 29;12(11):1034. doi: 10.3390/pharmaceutics12111034.
9
Biomimetic Synthesis and Evaluation of Interconnected Bimodal Mesostructured MSF@Poly(Ethyleneimine)s for Improved Drug Loading and Oral Adsorption of the Poorly Water-Soluble Drug, Ibuprofen.仿生合成及评价互穿双模态介孔 MSF@聚(亚乙基亚胺)用于改善难溶性药物布洛芬的载药和口服吸附
Int J Nanomedicine. 2020 Oct 5;15:7451-7468. doi: 10.2147/IJN.S272796. eCollection 2020.
10
Optimising the release rate of naproxen liqui-pellet: a new technology for emerging novel oral dosage form.优化萘普生液体微丸的释放速率:一种新兴新型口服剂型的新技术。
Drug Deliv Transl Res. 2020 Feb;10(1):43-58. doi: 10.1007/s13346-019-00659-6.